Valproic Acid, an Antiepileptic Drug with Histone Deacetylase Inhibitory Activity, Potentiates the Cytotoxic Effect of Apo2L/TRAIL on Cultured Thoracic Cancer Cells through Mitochondria-Dependent Caspase Activation
Inhibitors of histone deacetylases have been shown to enhance the sensitivity of cancer cells to tumor necrosis factor-related apoptosis-inducing ligand TRAIL-mediated cytotoxicity. Valproic acid (VA), a commonly used antiepileptic agent whose pharmacokinetics and toxicity profiles are well describe...
Saved in:
Published in | Neoplasia (New York, N.Y.) Vol. 8; no. 6; pp. 446 - 457 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.06.2006
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Inhibitors of histone deacetylases have been shown to enhance the sensitivity of cancer cells to tumor necrosis factor-related apoptosis-inducing ligand TRAIL-mediated cytotoxicity. Valproic acid (VA), a commonly used antiepileptic agent whose pharmacokinetics and toxicity profiles are well described, is a histone deacetylase inhibitor. This project aims to evaluate if VA can potentiate Apo2L/TRAIL-mediated cytotoxicity in cultured thoracic cancer cells and to elucidate the underlying molecular mechanism responsible for this effect. VA sensitized cultured thoracic cancer cells to Apo2L/TRAIL, as indicated by a 4-fold to a >20-fold reduction of Apo2L/TRAIL IC50 values in combination-treated cells. Although VA (0.5–5 mM) or Apo2L/TRAIL (20 ng/ml) induced less than 20% cell death, VA + Apo2L/TRAIL combinations caused 60% to 90% apoptosis of cancer cells. Moreover, substantial activation of caspases 8, 9, and 3, which was observed only in cells treated with the drug combinations, was completely suppressed by BcI2 overexpression or by the caspase 9 inhibitor. Both the caspase 9 inhibitor and BcI2 completely abrogated the substantial cytotoxicity and apoptosis induced by this combination, thus highlighting the pivotal role of the type II pathway in this process. These findings provide a rationale for the development of VA and Apo2L/TRAIL combination as a novel molecular therapeutic regimen for thoracic cancers. |
---|---|
AbstractList | Inhibitors of histone deacetylases have been shown to enhance the sensitivity of cancer cells to tumor necrosis factor-related apoptosis-inducing ligand TRAIL-mediated cytotoxicity. Valproic acid (VA), a commonly used antiepileptic agent whose pharmacokinetics and toxicity profiles are well described, is a histone deacetylase inhibitor. This project aims to evaluate if VA can potentiate Apo2L/TRAIL-mediated cytotoxicity in cultured thoracic cancer cells and to elucidate the underlying molecular mechanism responsible for this effect. VA sensitized cultured thoracic cancer cells to Apo2L/TRAIL, as indicated by a 4-fold to a >20-fold reduction of Apo2L/TRAIL IC50 values in combination-treated cells. Although VA (0.5-5 mM) or Apo2L/TRAIL (20 ng/ml) induced less than 20% cell death, VA + Apo2L/TRAIL combinations caused 60% to 90% apoptosis of cancer cells. Moreover, substantial activation of caspases 8, 9, and 3, which was observed only in cells treated with the drug combination, was completely suppressed by Bcl2 overexpression or by the caspase 9 inhibitor. Both the caspase 9 inhibitor and Bcl2 completely abrogated the substantial cytotoxicity and apoptosis induced by this combination, thus highlighting the pivotal role of the type II pathway in this process. These findings provide a rationale for the development of VA and Apo2L/TRAIL combination as a novel molecular therapeutic for thoracic cancers. Inhibitors of histone deacetylases have been shown to enhance the sensitivity of cancer cells to tumor necrosis factor-related apoptosis-inducing ligand TRAIL-mediated cytotoxicity. Valproic acid (VA), a commonly used antiepileptic agent whose pharmacokinetics and toxicity profiles are well described, is a histone deacetylase inhibitor. This project aims to evaluate if VA can potentiate Apo2L/TRAIL-mediated cytotoxicity in cultured thoracic cancer cells and to elucidate the underlying molecular mechanism responsible for this effect. VA sensitized cultured thoracic cancer cells to Apo2L/TRAIL, as indicated by a 4-fold to a >20-fold reduction of Apo2L/TRAIL IC50 values in combination-treated cells. Although VA (0.5–5 mM) or Apo2L/TRAIL (20 ng/ml) induced less than 20% cell death, VA + Apo2L/TRAIL combinations caused 60% to 90% apoptosis of cancer cells. Moreover, substantial activation of caspases 8, 9, and 3, which was observed only in cells treated with the drug combinations, was completely suppressed by BcI2 overexpression or by the caspase 9 inhibitor. Both the caspase 9 inhibitor and BcI2 completely abrogated the substantial cytotoxicity and apoptosis induced by this combination, thus highlighting the pivotal role of the type II pathway in this process. These findings provide a rationale for the development of VA and Apo2L/TRAIL combination as a novel molecular therapeutic regimen for thoracic cancers. |
Author | Chua, Alex Ziauddin, M. Firdos Reddy, Rishindra M. Tsai, Wilson Cole, George W. Maxhimer, Justin B. Schrump, David S. Nguyen, Dao M. Baras, Aris Yeow, Wen-Shuz |
Author_xml | – sequence: 1 givenname: M. Firdos surname: Ziauddin fullname: Ziauddin, M. Firdos – sequence: 2 givenname: Wen-Shuz surname: Yeow fullname: Yeow, Wen-Shuz – sequence: 3 givenname: Justin B. surname: Maxhimer fullname: Maxhimer, Justin B. – sequence: 4 givenname: Aris surname: Baras fullname: Baras, Aris – sequence: 5 givenname: Alex surname: Chua fullname: Chua, Alex – sequence: 6 givenname: Rishindra M. surname: Reddy fullname: Reddy, Rishindra M. – sequence: 7 givenname: Wilson surname: Tsai fullname: Tsai, Wilson – sequence: 8 givenname: George W. surname: Cole fullname: Cole, George W. – sequence: 9 givenname: David S. surname: Schrump fullname: Schrump, David S. – sequence: 10 givenname: Dao M. surname: Nguyen fullname: Nguyen, Dao M. email: dao_nguyen@nih.gov |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16820090$$D View this record in MEDLINE/PubMed |
BookMark | eNptkU1v1DAQhiNURD_gwB9AviI1rZ3E-TiusoWutAiEFq7RxB5vXKV2ZDuF_FF-D97dCjhwsjV6_Mx43svkzFiDSfKW0RvGm_zWoL2hvM7yF8kFK6oy5bwuz_65nyeX3j9QykpWVa-Sc1bWGaUNvUh-fYdxclYLshJaXhMwZGWCxkmPOIVYXrt5T37oMJB77UPsS9YIAsMygkeyMYPudbBuie-DftJhuSZfbMDogICehAFJuwQb7M8ou1MKRSBWkdVks-3t7utqsyXWkHYew-xQkt1gHYiItmAEOtLiOB4szs77gXyKrcRgjXQa0jVOaGTsFFk_HaY5jgBBW_M6ealg9Pjm-bxKvn2427X36fbzx0272qaiyOqQVhVkyAVXinHKKEchCyUzAU2BFDIGrBY9VQCNEHnJWaEY0APPgHMh8_wq2Zy80sJDNzn9CG7pLOjuWLBu34GLaxyxEzIr-p41vG94obIG-gaLirEcaC9z6KPr_cklnPXeofrjY7Q75NzFnLtjzpF9d2KnuX9E-Zd8DjYC-QnA-Psnja7zQmNcqdQuRhDH0__R_gZxRLvI |
CitedBy_id | crossref_primary_10_1158_1078_0432_CCR_08_1579 crossref_primary_10_1515_bmc_2010_020 crossref_primary_10_1007_s00262_007_0370_8 crossref_primary_10_2174_0929867325666180713155702 crossref_primary_10_1021_mp200597r crossref_primary_10_1038_sj_cgt_7701120 crossref_primary_10_1097_JTO_0b013e3181bc9419 crossref_primary_10_1016_j_jtcvs_2006_07_025 crossref_primary_10_1111_j_1365_2141_2010_08211_x crossref_primary_10_4161_cbt_19293 crossref_primary_10_1016_j_canlet_2008_06_027 crossref_primary_10_1016_j_canlet_2015_12_016 crossref_primary_10_1097_JTO_0b013e318217b6c8 crossref_primary_10_1016_j_ctrv_2007_11_003 crossref_primary_10_1016_j_eplepsyres_2018_11_006 crossref_primary_10_1593_neo_81372 crossref_primary_10_1155_2010_479364 crossref_primary_10_1007_s00280_013_2223_9 crossref_primary_10_1016_j_ejca_2010_03_021 crossref_primary_10_1097_SLA_0b013e3181758d0e crossref_primary_10_1016_j_exphem_2007_06_014 crossref_primary_10_1016_j_yexcr_2012_02_005 crossref_primary_10_1038_gt_2010_5 crossref_primary_10_1016_j_jss_2007_03_048 crossref_primary_10_3892_etm_2011_202 crossref_primary_10_1016_j_cellimm_2013_04_011 crossref_primary_10_1007_s00381_011_1673_9 crossref_primary_10_1016_S1734_1140_12_70856_3 crossref_primary_10_1158_1535_7163_MCT_12_0054 crossref_primary_10_1186_s13045_022_01313_4 crossref_primary_10_1016_j_canlet_2009_02_042 crossref_primary_10_1016_j_taap_2020_115363 crossref_primary_10_3892_ijo_2016_3525 crossref_primary_10_1074_jbc_M110_172767 crossref_primary_10_1007_s10863_006_9055_9 crossref_primary_10_1016_j_drup_2009_11_001 crossref_primary_10_1007_s11523_015_0370_0 crossref_primary_10_1016_j_phrs_2021_105976 crossref_primary_10_1016_j_toxrep_2014_05_005 crossref_primary_10_1016_j_canlet_2010_09_012 crossref_primary_10_1016_j_phrs_2020_104786 crossref_primary_10_1593_neo_07968 |
Cites_doi | 10.1038/sj.cdd.4401187 10.1038/sj.onc.1206127 10.1182/blood-2002-09-2975 10.1002/med.10017 10.1158/0008-5472.CAN-04-2006 10.1038/sj.onc.1207970 10.1038/sj.bjc.6602487 10.1038/sj.cdd.4401088 10.1038/sj.cdd.4400783 10.1158/1078-0432.CCR-05-9006 10.1158/1535-7163.MCT-04-0186 10.1093/emboj/cdg315 10.1038/sj.onc.1207830 10.1172/JCI6926 10.1517/13543784.13.1.21 10.1038/sj.cdd.4400598 10.1074/jbc.M101287200 10.3816/CLC.2002.n.027 10.1056/NEJMra035536 10.1016/j.drup.2004.03.002 10.1016/j.bbrc.2003.12.074 10.1093/emboj/17.6.1675 10.1016/S1359-6101(03)00029-7 10.1038/86397 10.4161/cc.4.4.1564 10.1038/sj.onc.1208585 10.1002/ijc.10376 10.1083/jcb.144.2.281 10.1158/1535-7163.1397.3.11 10.1021/bi992242l 10.1016/S1097-2765(03)00051-0 10.1165/ajrcmb.25.1.4472 10.1038/sj.neo.7900270 10.1158/0008-5472.CAN-03-0799 10.1038/sj.onc.1207523 10.1053/j.seminoncol.2005.07.007 10.1038/sj.cgt.7700792 10.1111/j.1349-7006.2004.tb02181.x 10.1056/NEJMra035010 10.1073/pnas.96.20.10964 10.1593/neo.04655 10.1038/sj.cdd.4400739 10.1073/pnas.191208598 10.1016/S0006-291X(03)00615-6 10.1158/0008-5472.CAN-03-2629 10.1016/S0955-0674(99)80034-9 10.1158/0008-5472.CAN-04-0408 10.1158/1078-0432.CCR-03-0100 10.1016/j.ymthe.2004.12.008 10.1093/emboj/20.24.6969 10.1074/jbc.271.22.12687 10.1038/sj.cdd.4401535 10.1038/sj.onc.1207704 10.1038/nm0302-274 10.1093/jnci/94.7.504 10.1093/carcin/bgh188 10.1074/jbc.M000811200 10.1016/j.yexcr.2004.04.038 10.2174/1381612043383980 10.1002/ijc.21283 10.1056/NEJM199601183340308 10.1016/S0006-2952(03)00509-4 10.1146/annurev.physiol.60.1.619 |
ContentType | Journal Article |
Copyright | 2006 Neoplasia Press, Inc. |
Copyright_xml | – notice: 2006 Neoplasia Press, Inc. |
DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION DOA |
DOI | 10.1593/neo.05823 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1476-5586 1522-8002 |
EndPage | 457 |
ExternalDocumentID | oai_doaj_org_article_cd24bb195b954f29ab9e47113a0bd3ab 10_1593_neo_05823 16820090 S1476558606800278 |
Genre | Journal Article Research Support, N.I.H., Intramural |
GrantInformation_xml | – fundername: Intramural NIH HHS |
GroupedDBID | --- .1- .FO 0SF 123 1P~ 29M 2WC 36B 4.4 457 53G 6I. AACTN AAEDT AAEDW AAFTH AAIKJ AALRI AAXUO ABDBF ABFRF ABMAC ACGFO ACGFS ACPRK ADBBV ADEZE AEFWE AENEX AEVXI AEXQZ AFCTW AFRHN AFTJW AGHFR AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BAWUL BCNDV CAG COF CS3 DIK DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX F5P FDB GROUPED_DOAJ GX1 HYE IPNFZ IXB KQ8 M~E NCXOZ OC~ OK1 OO- P2P RIG RNS ROL RPM SSZ SV3 UNMZH W2D WOQ Z5R 0R~ ADVLN AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION |
ID | FETCH-LOGICAL-c428t-77a2e5c5ff150105ecd4fd2ca94e0a21a18cb0faa9cc36514f1a05c5f1a55cd33 |
IEDL.DBID | DOA |
ISSN | 1476-5586 |
IngestDate | Tue Oct 22 15:06:51 EDT 2024 Thu Sep 26 19:55:19 EDT 2024 Sat Sep 28 07:43:00 EDT 2024 Fri Feb 23 02:30:06 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | malignant pleural mesothelioma SMAC/DIABLO esophageal cancer TRAIL NSCLC mitochondria MPM VA MTT lung cancer GFP Histone deacetylase inhibitor TUNEL EsC BcI2 Apo2L/TRAIL caspases HDACI |
Language | English |
License | http://creativecommons.org/licenses/by-nc-nd/3.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c428t-77a2e5c5ff150105ecd4fd2ca94e0a21a18cb0faa9cc36514f1a05c5f1a55cd33 |
OpenAccessLink | https://doaj.org/article/cd24bb195b954f29ab9e47113a0bd3ab |
PMID | 16820090 |
PageCount | 12 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_cd24bb195b954f29ab9e47113a0bd3ab crossref_primary_10_1593_neo_05823 pubmed_primary_16820090 elsevier_sciencedirect_doi_10_1593_neo_05823 |
PublicationCentury | 2000 |
PublicationDate | 2006-06-01 |
PublicationDateYYYYMMDD | 2006-06-01 |
PublicationDate_xml | – month: 06 year: 2006 text: 2006-06-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Neoplasia (New York, N.Y.) |
PublicationTitleAlternate | Neoplasia |
PublicationYear | 2006 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
References | Blaheta, Cinatl (bib47) 2002; 22 Ruefli, Ausserlechner, Bernhard, Sutton, Tainton, Kofler, Smyth, Johnstone (bib42) 2001; 98 Rosato, Almenara, Dai, Grant (bib67) 2003; 2 Jin, Yang, Fong, Totpal, Lawrence, Zheng, Ross, Koeppen, Schwall, Ashkenazi (bib26) 2004; 64 Brodie, Dichter (bib48) 1996; 334 Ruffolo, Breckenridge, Nguyen, Goping, Gross, Korsmeyer, Li, Yuan, Shore (bib12) 2000; 7 Almasan, Ashkenazi (bib1) 2003; 14 Piekarz, Bates (bib40) 2004; 10 Ashkenazi, Dixit (bib6) 1999; 11 Boatright, Renatus, Scott, Sperandio, Shin, Pedersen, Ricci, Edris, Sutherlin, Green (bib9) 2003; 11 Nakata, Yoshida, Horinaka, Shiraishi, Wakada, Sakai (bib59) 2004; 23 Vanoosten, Moore, Ludwig, Griffith (bib56) 2005; 11 Muhlethaler-Mottet, Bourloud, Auderset, Joseph, Gross (bib28) 2004; 23 Garcia-Morales, Gomez-Martinez, Carrato, Martinez-Lacaci, Barbera, Soto, Carrasco-Garcia, Menendez-Gutierrez, Castro-Galache, Ferragut (bib44) 2005; 4 Wajant, Haas, Schwenzer, Muhlenbeck, Kreuz, Schubert, Grell, Smith, Scheurich (bib70) 2000; 275 Saelens, Festjens, Vande, van Gurp, van Loo, Vandenabeele (bib16) 2004; 23 Enzinger, Mayer (bib62) 2003; 349 Gottlicher, Minucci, Zhu, Kramer, Schimpf, Giavara, Sleeman, Lo, Nervi, Pelicci (bib54) 2001; 20 Pukac, Kanakaraj, Humphreys, Alderson, Bloom, Sung, Riccobene, Johnson, Fiscella, Mahoney (bib64) 2005; 92 Inoue, Shiraki, Ohmori, Sakai, Deguchi, Yamanaka, Okano, Nakano (bib69) 2002; 9 Gurvich, Tsygankova, Meinkoth, Klein (bib49) 2004; 64 Neuzil, Swettenham, Gellert (bib66) 2004; 314 Pitti, Marsters, Ruppert, Donahue, Moore, Ashkenazi (bib5) 1996; 271 Salvesen, Dixit (bib8) 1999; 96 Scorrano, Korsmeyer (bib14) 2003; 304 Hymowitz, O'Connell, Ultsch, Hurst, Totpal, Ashkenazi, de Vos, Kelley (bib3) 2000; 39 Korsmeyer, Wei, Saito, Weiler, Oh, Schlesinger (bib13) 2000; 7 Ravi, Bedi (bib33) 2002; 62 Jaboin, Wild, Hamidi, Khanna, Kim, Robey, Bates, Thiele (bib37) 2002; 62 Kelly, Richon, O'Connor, Curley, MacGregor-Curtelli, Tong, Klang, Schwartz, Richardson, Rosa (bib39) 2003; 9 Kim, Koo, Jeon, Kim, Lee, Hong, Jeong (bib30) 2003; 63 LeBlanc, Lawrence, Varfolomeev, Totpal, Morlan, Schow, Fong, Schwall, Sinicropi, Ashkenazi (bib34) 2002; 8 Kim, Ajaz, Lokshin, Lee (bib25) 2003; 9 Fulda, Jeremias, Debatin (bib32) 2004; 23 Seynaeve, Kazanietz, Blumberg, Sausville, Worland (bib53) 1994; 45 LeBlanc, Ashkenazi (bib4) 2003; 10 Kondo, Yamasaki, Sugie, Teratani, Kan, Imamura, Shimada (bib23) 2005; 118 Zhang, Fang (bib22) 2005; 12 Sayers, Brooks, Koh, Ma, Seki, Raziuddin, Blazar, Zhang, Elliott, Murphy (bib31) 2003; 102 Nicholson (bib7) 1999; 6 Dunant, Pignon, Le Chevalier (bib46) 2005; 11 Inoue, MacFarlane, Harper, Wheat, Dyer, Cohen (bib65) 2004; 11 Lacour, Micheau, Hammann, Drouineaud, Tschopp, Solary, Dimanche-Boitrel (bib24) 2003; 22 Doi, Soda, Oka, Tsurutani, Kitazaki, Nakamura, Fukuda, Yamada, Kamihira, Kohno (bib45) 2004; 3 Slee, Harte, Kluck, Wolf, Casiano, Newmeyer, Wang, Reed, Nicholson, Alnemri (bib72) 1999; 144 Evdokiou, Bouralexis, Atkins, Chai, Hay, Clayer, Findlay (bib29) 2002; 99 Charo, Finkelstein, Grewal, Restifo, Robbins, Rosenberg (bib55) 2005; 65 Kroemer, Dallaporta, Resche-Rigon (bib10) 1998; 60 Scaffidi, Fulda, Srinivasan, Friesen, Li, Tomaselli, Debatin, Krammer, Peter (bib15) 1998; 17 Kelley, Harris, Xie, DeForge, Totpal, Bussiere, Fox (bib20) 2001; 299 Marks, Jiang (bib43) 2005; 4 Ozoren, el Deiry (bib17) 2002; 4 Yagita, Takeda, Hayakawa, Smyth, Okumura (bib2) 2004; 95 van Loo, Saelens, van Gurp, MacFarlane, Martin, Vandenabeele (bib11) 2002; 9 Lawrence, Shahrokh, Marsters, Achilles, Shih, Mounho, Hillan, Totpal, DeForge, Schow (bib18) 2001; 7 Yu, Guo, Marcu, Neckers, Nguyen, Chen, Schrump (bib41) 2002; 94 Fandy, Shankar, Ross, Sausville, Srivastava (bib71) 2005; 7 Phiel, Zhang, Huang, Guenther, Lazar, Klein (bib50) 2001; 276 Guo, Sigua, Tao, Bali, George, Li, Wittmann, Moscinski, Atadja, Bhalla (bib60) 2004; 64 Zhang, Gillespie, Borrow, Hersey (bib68) 2003; 66 Liu, Bodle, Chen JY Gao, Rosen, Broaddus (bib27) 2001; 25 Shankar, Srivastava (bib21) 2004; 7 Kim, Park, Lee, Kwon (bib57) 2004; 25 Ashkenazi, Pai, Fong, Leung, Lawrence, Marsters, Blackie, Chang, McMurtrey, Hebert (bib19) 1999; 104 Schrump, Nguyen (bib36) 2005; 32 Rosato, Grant (bib35) 2004; 13 Chopin, Slomianny, Hondermarck, Le Bourhis (bib58) 2004; 298 Singh, Shankar, Srivastava (bib61) 2005; 24 Schrump, Nguyen, Kunst, Hancox, Figg, Steinberg, Pishchik, Becerra (bib38) 2002; 4 Kramer, Zhu, Ostendorff, Golebiewski, Tiefenbach, Peters, Brill, Groner, Bach, Heinzel (bib51) 2003; J22 Takai, Desmond, Kumagai, Gui, Said, Whittaker, Miyakawa, Koeffler (bib52) 2004; 10 Spira, Ettinger (bib63) 2004; 350 10651627 - Biochemistry. 2000 Feb 1;39(4):633-40 12637321 - Blood. 2003 Jul 1;102(1):303-10 11535817 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10833-8 14871841 - Cancer Res. 2004 Feb 1;64(3):1079-86 14657432 - N Engl J Med. 2003 Dec 4;349(23):2241-52 11956660 - Int J Mol Med. 2002 May;9(5):521-5 14706169 - Clin Lung Cancer. 2002 Nov;4(3):186-92 15059915 - Cancer Res. 2004 Apr 1;64(7):2580-9 15753400 - Cancer Res. 2005 Mar 1;65(5):2001-8 15256461 - Cancer Res. 2004 Jul 15;64(14):4900-5 12414635 - Cancer Res. 2002 Nov 1;62(21):6108-15 15771957 - Mol Ther. 2005 Apr;11(4):542-52 15608694 - Cell Death Differ. 2004 Dec;11 Suppl 2:S193-206 11283636 - Nat Med. 2001 Apr;7(4):383-5 12912965 - Clin Cancer Res. 2003 Aug 1;9(8):3134-41 12566305 - Cancer Res. 2003 Feb 1;63(3):621-6 15142888 - Carcinogenesis. 2004 Oct;25(10):1813-20 15077149 - Oncogene. 2004 Apr 12;23(16):2861-74 14715264 - Biochem Biophys Res Commun. 2004 Jan 30;314(1):186-91 12407450 - Neoplasia. 2002 Nov-Dec;4(6):551-7 15208660 - Oncogene. 2004 Aug 19;23(37):6261-71 9501089 - EMBO J. 1998 Mar 16;17(6):1675-87 15279609 - Curr Pharm Des. 2004;10(19):2289-98 12232790 - Cell Death Differ. 2002 Oct;9(10):1031-42 11929951 - J Natl Cancer Inst. 2002 Apr 3;94(7):504-13 15542778 - Mol Cancer Ther. 2004 Nov;3(11):1397-402 11992538 - Int J Cancer. 2002 Jun 1;99(4):491-504 16093438 - Mol Cancer Ther. 2005 Aug;4(8):1222-30 14680450 - Expert Opin Investig Drugs. 2004 Jan;13(1):21-38 15504243 - Cancer Sci. 2004 Oct;95(10):777-83 15897906 - Oncogene. 2005 Jul 7;24(29):4609-23 12840003 - EMBO J. 2003 Jul 1;22(13):3411-20 12787570 - Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):337-48 14736930 - N Engl J Med. 2004 Jan 22;350(4):379-92 15738652 - Cell Cycle. 2005 Apr;4(4):549-51 14555232 - Biochem Pharmacol. 2003 Oct 15;66(8):1537-45 8022414 - Mol Pharmacol. 1994 Jun;45(6):1207-14 10578171 - Cell Death Differ. 1999 Nov;6(11):1028-42 10209153 - Curr Opin Cell Biol. 1999 Apr;11(2):255-60 12655296 - Cell Death Differ. 2003 Jan;10(1):66-75 15846298 - Br J Cancer. 2005 Apr 25;92(8):1430-41 10823821 - J Biol Chem. 2000 Aug 11;275(32):24357-66 11473107 - J Biol Chem. 2001 Sep 28;276(39):36734-41 9922454 - J Cell Biol. 1999 Jan 25;144(2):281-92 12210556 - Med Res Rev. 2002 Sep;22(5):492-511 15158769 - Drug Resist Updat. 2004 Apr;7(2):139-56 15094781 - Oncogene. 2004 Jul 15;23(32):5415-25 16000606 - Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5017s-5021s 10411544 - J Clin Invest. 1999 Jul;104(2):155-62 11139284 - Cell Death Differ. 2000 Nov;7(11):1101-8 14707268 - Mol Cancer Ther. 2003 Dec;2(12):1273-84 14871994 - Clin Cancer Res. 2004 Feb 1;10(3):1141-9 10500109 - Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):10964-7 11472983 - Am J Respir Cell Mol Biol. 2001 Jul;25(1):111-8 11912124 - Cancer Res. 2002 Mar 15;62(6):1583-7 8663110 - J Biol Chem. 1996 May 31;271(22):12687-90 8531974 - N Engl J Med. 1996 Jan 18;334(3):168-75 16210090 - Semin Oncol. 2005 Oct;32(5):488-502 15550937 - Cancer Gene Ther. 2005 Mar;12(3):228-37 11875499 - Nat Med. 2002 Mar;8(3):274-81 11561060 - J Pharmacol Exp Ther. 2001 Oct;299(1):31-8 9558479 - Annu Rev Physiol. 1998;60:619-42 14506144 - Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88 15361826 - Oncogene. 2004 Oct 7;23(46):7611-20 12729577 - Biochem Biophys Res Commun. 2003 May 9;304(3):437-44 12660816 - Oncogene. 2003 Mar 27;22(12):1807-16 15265702 - Exp Cell Res. 2004 Aug 15;298(2):560-73 16003725 - Int J Cancer. 2006 Jan 1;118(1):230-42 12620239 - Mol Cell. 2003 Feb;11(2):529-41 16026644 - Neoplasia. 2005 Jul;7(7):646-57 11742974 - EMBO J. 2001 Dec 17;20(24):6969-78 11175253 - Cell Death Differ. 2000 Dec;7(12):1166-73 Ashkenazi (10.1593/neo.05823_bib19) 1999; 104 Gurvich (10.1593/neo.05823_bib49) 2004; 64 Nakata (10.1593/neo.05823_bib59) 2004; 23 Schrump (10.1593/neo.05823_bib38) 2002; 4 Vanoosten (10.1593/neo.05823_bib56) 2005; 11 Evdokiou (10.1593/neo.05823_bib29) 2002; 99 Fulda (10.1593/neo.05823_bib32) 2004; 23 Kim (10.1593/neo.05823_bib57) 2004; 25 Zhang (10.1593/neo.05823_bib68) 2003; 66 Nicholson (10.1593/neo.05823_bib7) 1999; 6 Ruffolo (10.1593/neo.05823_bib12) 2000; 7 Hymowitz (10.1593/neo.05823_bib3) 2000; 39 Kelly (10.1593/neo.05823_bib39) 2003; 9 Gottlicher (10.1593/neo.05823_bib54) 2001; 20 Sayers (10.1593/neo.05823_bib31) 2003; 102 Rosato (10.1593/neo.05823_bib67) 2003; 2 Lawrence (10.1593/neo.05823_bib18) 2001; 7 LeBlanc (10.1593/neo.05823_bib34) 2002; 8 Brodie (10.1593/neo.05823_bib48) 1996; 334 Pitti (10.1593/neo.05823_bib5) 1996; 271 Kim (10.1593/neo.05823_bib25) 2003; 9 Yagita (10.1593/neo.05823_bib2) 2004; 95 Piekarz (10.1593/neo.05823_bib40) 2004; 10 Takai (10.1593/neo.05823_bib52) 2004; 10 Zhang (10.1593/neo.05823_bib22) 2005; 12 Kim (10.1593/neo.05823_bib30) 2003; 63 Rosato (10.1593/neo.05823_bib35) 2004; 13 Seynaeve (10.1593/neo.05823_bib53) 1994; 45 Ravi (10.1593/neo.05823_bib33) 2002; 62 Inoue (10.1593/neo.05823_bib69) 2002; 9 Muhlethaler-Mottet (10.1593/neo.05823_bib28) 2004; 23 Wajant (10.1593/neo.05823_bib70) 2000; 275 Ruefli (10.1593/neo.05823_bib42) 2001; 98 Doi (10.1593/neo.05823_bib45) 2004; 3 Kroemer (10.1593/neo.05823_bib10) 1998; 60 Spira (10.1593/neo.05823_bib63) 2004; 350 Kramer (10.1593/neo.05823_bib51) 2003; J22 Almasan (10.1593/neo.05823_bib1) 2003; 14 Neuzil (10.1593/neo.05823_bib66) 2004; 314 Charo (10.1593/neo.05823_bib55) 2005; 65 Kelley (10.1593/neo.05823_bib20) 2001; 299 Saelens (10.1593/neo.05823_bib16) 2004; 23 Ashkenazi (10.1593/neo.05823_bib6) 1999; 11 Salvesen (10.1593/neo.05823_bib8) 1999; 96 Ozoren (10.1593/neo.05823_bib17) 2002; 4 Boatright (10.1593/neo.05823_bib9) 2003; 11 Chopin (10.1593/neo.05823_bib58) 2004; 298 Schrump (10.1593/neo.05823_bib36) 2005; 32 van Loo (10.1593/neo.05823_bib11) 2002; 9 Phiel (10.1593/neo.05823_bib50) 2001; 276 Scaffidi (10.1593/neo.05823_bib15) 1998; 17 Jaboin (10.1593/neo.05823_bib37) 2002; 62 Shankar (10.1593/neo.05823_bib21) 2004; 7 Garcia-Morales (10.1593/neo.05823_bib44) 2005; 4 Kondo (10.1593/neo.05823_bib23) 2005; 118 Inoue (10.1593/neo.05823_bib65) 2004; 11 Slee (10.1593/neo.05823_bib72) 1999; 144 Dunant (10.1593/neo.05823_bib46) 2005; 11 LeBlanc (10.1593/neo.05823_bib4) 2003; 10 Jin (10.1593/neo.05823_bib26) 2004; 64 Scorrano (10.1593/neo.05823_bib14) 2003; 304 Blaheta (10.1593/neo.05823_bib47) 2002; 22 Yu (10.1593/neo.05823_bib41) 2002; 94 Liu (10.1593/neo.05823_bib27) 2001; 25 Lacour (10.1593/neo.05823_bib24) 2003; 22 Fandy (10.1593/neo.05823_bib71) 2005; 7 Korsmeyer (10.1593/neo.05823_bib13) 2000; 7 Pukac (10.1593/neo.05823_bib64) 2005; 92 Guo (10.1593/neo.05823_bib60) 2004; 64 Marks (10.1593/neo.05823_bib43) 2005; 4 Singh (10.1593/neo.05823_bib61) 2005; 24 Enzinger (10.1593/neo.05823_bib62) 2003; 349 |
References_xml | – volume: 20 start-page: 6969 year: 2001 end-page: 6978 ident: bib54 article-title: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells publication-title: EMBO J contributor: fullname: Pelicci – volume: 7 start-page: 1101 year: 2000 end-page: 1108 ident: bib12 article-title: BID-dependent and BID-independent pathways for BAX insertion into mitochondria publication-title: Cell Death Differ contributor: fullname: Shore – volume: 62 start-page: 6108 year: 2002 end-page: 6115 ident: bib37 article-title: MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors publication-title: Cancer Res contributor: fullname: Thiele – volume: 95 start-page: 777 year: 2004 end-page: 783 ident: bib2 article-title: TRAIL and its receptors as targets for cancer therapy publication-title: Cancer Sci contributor: fullname: Okumura – volume: 45 start-page: 1207 year: 1994 end-page: 1214 ident: bib53 article-title: Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue publication-title: Mol Pharmacol contributor: fullname: Worland – volume: 9 start-page: 3134 year: 2003 end-page: 3141 ident: bib25 article-title: Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis publication-title: Clin Cancer Res contributor: fullname: Lee – volume: 4 start-page: 186 year: 2002 end-page: 192 ident: bib38 article-title: Phase I study of sequential deoxyazacytidine/depsipeptide infusion in patients with malignancies involving lungs or pleura publication-title: Clin Lung Cancer contributor: fullname: Becerra – volume: 24 start-page: 4609 year: 2005 end-page: 4623 ident: bib61 article-title: HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma publication-title: Oncogene contributor: fullname: Srivastava – volume: 23 start-page: 6261 year: 2004 end-page: 6271 ident: bib59 article-title: Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/AP02-L in human malignant tumor cells publication-title: Oncogene contributor: fullname: Sakai – volume: 25 start-page: 1813 year: 2004 end-page: 1820 ident: bib57 article-title: Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Spi sites in colon cancer cells publication-title: Carcinogenesis contributor: fullname: Kwon – volume: 12 start-page: 228 year: 2005 end-page: 237 ident: bib22 article-title: Mechanisms of resistance to TRAIL-induced apoptosis in cancer publication-title: Cancer Gene Ther contributor: fullname: Fang – volume: 11 start-page: 5017s year: 2005 end-page: 5021s ident: bib46 article-title: Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial publication-title: Clin Cancer Res contributor: fullname: Le Chevalier – volume: 60 start-page: 619 year: 1998 end-page: 642 ident: bib10 article-title: The mitochondrial death/life regulator in apoptosis and necrosis publication-title: Annu Rev Physiol contributor: fullname: Resche-Rigon – volume: 349 start-page: 2241 year: 2003 end-page: 2252 ident: bib62 article-title: Esophageal cancer publication-title: N Engl J Med contributor: fullname: Mayer – volume: 304 start-page: 437 year: 2003 end-page: 444 ident: bib14 article-title: Mechanisms of cytochrome c release by proapoptotic BCL-2 family members publication-title: Biochem Biophys Res Commun contributor: fullname: Korsmeyer – volume: 17 start-page: 1675 year: 1998 end-page: 1687 ident: bib15 article-title: Two CD95 (APO-1/Fas) signaling pathways publication-title: EMBO J contributor: fullname: Peter – volume: 4 start-page: 549 year: 2005 end-page: 551 ident: bib43 article-title: Histone deacetylase inhibitors in programmed cell death and cancer therapy publication-title: Cell Cycle contributor: fullname: Jiang – volume: 65 start-page: 2001 year: 2005 end-page: 2008 ident: bib55 article-title: Bcl-2 overexpression enhances tumor-specific T-cell survival publication-title: Cancer Res contributor: fullname: Rosenberg – volume: 64 start-page: 2580 year: 2004 end-page: 2589 ident: bib60 article-title: Cotreatment with histone deacetylase inhibitor LA0824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells publication-title: Cancer Res contributor: fullname: Bhalla – volume: 2 start-page: 1273 year: 2003 end-page: 1284 ident: bib67 article-title: Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells publication-title: Mol Cancer Ther contributor: fullname: Grant – volume: 63 start-page: 621 year: 2003 end-page: 626 ident: bib30 article-title: Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines publication-title: Cancer Res contributor: fullname: Jeong – volume: 271 start-page: 12687 year: 1996 end-page: 12690 ident: bib5 article-title: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family publication-title: J Biol Chem contributor: fullname: Ashkenazi – volume: 104 start-page: 155 year: 1999 end-page: 162 ident: bib19 article-title: Safety and antitumor activity of recombinant soluble Apo2 ligand publication-title: J Clin Invest contributor: fullname: Hebert – volume: 66 start-page: 1537 year: 2003 end-page: 1545 ident: bib68 article-title: The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis publication-title: Biochem Pharmacol contributor: fullname: Hersey – volume: 276 start-page: 36734 year: 2001 end-page: 36741 ident: bib50 article-title: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen publication-title: J Biol Chem contributor: fullname: Klein – volume: 275 start-page: 24357 year: 2000 end-page: 24366 ident: bib70 article-title: Inhibition of death receptormediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD) publication-title: J Biol Chem contributor: fullname: Scheurich – volume: 9 start-page: 1031 year: 2002 end-page: 1042 ident: bib11 article-title: The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet publication-title: Cell Death Differ contributor: fullname: Vandenabeele – volume: 22 start-page: 1807 year: 2003 end-page: 1816 ident: bib24 article-title: Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells publication-title: Oncogene contributor: fullname: Dimanche-Boitrel – volume: 4 start-page: 1222 year: 2005 end-page: 1230 ident: bib44 article-title: Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinomacell lines publication-title: Mol Cancer Ther contributor: fullname: Ferragut – volume: 7 start-page: 139 year: 2004 end-page: 156 ident: bib21 article-title: Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications publication-title: Drug Resist Updat contributor: fullname: Srivastava – volume: 7 start-page: 646 year: 2005 end-page: 657 ident: bib71 article-title: Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expres sions of cell cycle regulatory genes in multiple myeloma publication-title: Neoplasia contributor: fullname: Srivastava – volume: 10 start-page: 66 year: 2003 end-page: 75 ident: bib4 article-title: Apo2L/TRAIL and its death and decoy receptors publication-title: Cell Death Differ contributor: fullname: Ashkenazi – volume: 7 start-page: 383 year: 2001 end-page: 385 ident: bib18 article-title: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions publication-title: Nat Med contributor: fullname: Schow – volume: 118 start-page: 230 year: 2005 end-page: 242 ident: bib23 article-title: Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis inducing ligand against esophageal squamous cell carcinoma publication-title: Int J Cancer contributor: fullname: Shimada – volume: 3 start-page: 1397 year: 2004 end-page: 1402 ident: bib45 article-title: The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells publication-title: Mol Cancer Ther contributor: fullname: Kohno – volume: 96 start-page: 10964 year: 1999 end-page: 10967 ident: bib8 article-title: Caspase activation: the inducedproximity model publication-title: Proc Natl Acad Sci USA contributor: fullname: Dixit – volume: 23 start-page: 5415 year: 2004 end-page: 5425 ident: bib28 article-title: Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP publication-title: Oncogene contributor: fullname: Gross – volume: 10 start-page: 2289 year: 2004 end-page: 2298 ident: bib40 article-title: A review of depsipeptide and other histone deacetylase inhibitors in clinical trials publication-title: Curr Pharm Des contributor: fullname: Bates – volume: 22 start-page: 492 year: 2002 end-page: 511 ident: bib47 article-title: Anti-tumor mechanisms of valproate: a novel role for an old drug publication-title: Med Res Rev contributor: fullname: Cinatl – volume: 39 start-page: 633 year: 2000 end-page: 640 ident: bib3 article-title: A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/ TRAIL publication-title: Biochemistry contributor: fullname: Kelley – volume: 4 start-page: 551 year: 2002 end-page: 557 ident: bib17 article-title: Defining characteristics of types I and II apoptotic cells in response to TRAIL publication-title: Neoplasia contributor: fullname: el Deiry – volume: 98 start-page: 10833 year: 2001 end-page: 10838 ident: bib42 article-title: The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species publication-title: Proc Natl Acad Sci USA contributor: fullname: Johnstone – volume: 9 start-page: 521 year: 2002 end-page: 525 ident: bib69 article-title: Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis publication-title: Int J Mol Med contributor: fullname: Nakano – volume: 23 start-page: 7611 year: 2004 end-page: 7620 ident: bib32 article-title: Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells publication-title: Oncogene contributor: fullname: Debatin – volume: 6 start-page: 1028 year: 1999 end-page: 1042 ident: bib7 article-title: Caspase structure, proteolytic substrates, and function during apoptotic cell death publication-title: Cell Death Differ contributor: fullname: Nicholson – volume: 13 start-page: 21 year: 2004 end-page: 38 ident: bib35 article-title: Histone deacetylase inhibitors in clinical development publication-title: Expert Opin Investig Drugs contributor: fullname: Grant – volume: 23 start-page: 2861 year: 2004 end-page: 2874 ident: bib16 article-title: Toxic proteins released from mitochondria in cell death publication-title: Oncogene contributor: fullname: Vandenabeele – volume: 62 start-page: 1583 year: 2002 end-page: 1587 ident: bib33 article-title: Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindacmediated inhibition of Bcl-x(L) publication-title: Cancer Res contributor: fullname: Bedi – volume: 8 start-page: 274 year: 2002 end-page: 281 ident: bib34 article-title: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax publication-title: Nat Med contributor: fullname: Ashkenazi – volume: 64 start-page: 1079 year: 2004 end-page: 1086 ident: bib49 article-title: Histone deacetylase is a target of valproic acid-mediated cellular differentiation publication-title: Cancer Res contributor: fullname: Klein – volume: 32 start-page: 488 year: 2005 end-page: 502 ident: bib36 article-title: Targeting the epigenome for the treatment and prevention of lung cancer publication-title: Semin Oncol contributor: fullname: Nguyen – volume: 99 start-page: 491 year: 2002 end-page: 504 ident: bib29 article-title: Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis publication-title: Int J Cancer contributor: fullname: Findlay – volume: 102 start-page: 303 year: 2003 end-page: 310 ident: bib31 article-title: The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP publication-title: Blood contributor: fullname: Murphy – volume: 11 start-page: 542 year: 2005 end-page: 552 ident: bib56 article-title: Depsipeptide (FR901228 enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts publication-title: Mol Ther contributor: fullname: Griffith – volume: 9 start-page: 3578 year: 2003 end-page: 3588 ident: bib39 article-title: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously publication-title: Clin Cancer Res contributor: fullname: Rosa – volume: 10 start-page: 1141 year: 2004 end-page: 1149 ident: bib52 article-title: Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells publication-title: Clin Cancer Res contributor: fullname: Koeffler – volume: J22 start-page: 3411 year: 2003 end-page: 3420 ident: bib51 article-title: The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 publication-title: EMBO contributor: fullname: Heinzel – volume: 298 start-page: 560 year: 2004 end-page: 573 ident: bib58 article-title: Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1) publication-title: Exp Cell Res contributor: fullname: Le Bourhis – volume: 94 start-page: 504 year: 2002 end-page: 513 ident: bib41 article-title: Modulation of p53, ErbBI, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228 publication-title: J Natl Cancer Inst contributor: fullname: Schrump – volume: 11 start-page: S193 year: 2004 end-page: S206 ident: bib65 article-title: Histone deacetylase inhibitors potentiate TNF-related apoptosisinducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies publication-title: Cell Death Differ contributor: fullname: Cohen – volume: 314 start-page: 186 year: 2004 end-page: 191 ident: bib66 article-title: Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation publication-title: Biochem Biophys Res Commun contributor: fullname: Gellert – volume: 299 start-page: 31 year: 2001 end-page: 38 ident: bib20 article-title: Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: charac terization of in vivo efficacy, pharmacokinetics, and safety publication-title: J Pharmacol Exp Ther contributor: fullname: Fox – volume: 11 start-page: 255 year: 1999 end-page: 260 ident: bib6 article-title: Apoptosis control by death and decoy receptors publication-title: Curr Opin Cell Biol contributor: fullname: Dixit – volume: 350 start-page: 379 year: 2004 end-page: 392 ident: bib63 article-title: Multidisciplinary management of lung cancer publication-title: N Engl J Med contributor: fullname: Ettinger – volume: 144 start-page: 281 year: 1999 end-page: 292 ident: bib72 article-title: Ordering the cytochrome publication-title: J Cell Biol contributor: fullname: Alnemri – volume: 25 start-page: 111 year: 2001 end-page: 118 ident: bib27 article-title: Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines publication-title: Am J Respir Cell Mol Biol contributor: fullname: Broaddus – volume: 7 start-page: 1166 year: 2000 end-page: 1173 ident: bib13 article-title: Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c publication-title: Cell Death Differ contributor: fullname: Schlesinger – volume: 64 start-page: 4900 year: 2004 end-page: 4905 ident: bib26 article-title: Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with che motherapy to inhibit orthotopic lung tumor growth and improve survival publication-title: Cancer Res contributor: fullname: Ashkenazi – volume: 92 start-page: 1430 year: 2005 end-page: 1441 ident: bib64 article-title: HGSETRi, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo publication-title: Br J Cancer contributor: fullname: Mahoney – volume: 14 start-page: 337 year: 2003 end-page: 348 ident: bib1 article-title: Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy publication-title: Cytokine Growth Factor Rev contributor: fullname: Ashkenazi – volume: 11 start-page: 529 year: 2003 end-page: 541 ident: bib9 article-title: A unified model for apical caspase activations publication-title: Mol Cell contributor: fullname: Green – volume: 334 start-page: 168 year: 1996 end-page: 175 ident: bib48 article-title: Antiepileptic drugs publication-title: N Engl J Med contributor: fullname: Dichter – volume: 10 start-page: 66 year: 2003 ident: 10.1593/neo.05823_bib4 article-title: Apo2L/TRAIL and its death and decoy receptors publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4401187 contributor: fullname: LeBlanc – volume: 22 start-page: 1807 year: 2003 ident: 10.1593/neo.05823_bib24 article-title: Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells publication-title: Oncogene doi: 10.1038/sj.onc.1206127 contributor: fullname: Lacour – volume: 102 start-page: 303 year: 2003 ident: 10.1593/neo.05823_bib31 article-title: The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP publication-title: Blood doi: 10.1182/blood-2002-09-2975 contributor: fullname: Sayers – volume: 22 start-page: 492 year: 2002 ident: 10.1593/neo.05823_bib47 article-title: Anti-tumor mechanisms of valproate: a novel role for an old drug publication-title: Med Res Rev doi: 10.1002/med.10017 contributor: fullname: Blaheta – volume: 65 start-page: 2001 year: 2005 ident: 10.1593/neo.05823_bib55 article-title: Bcl-2 overexpression enhances tumor-specific T-cell survival publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-2006 contributor: fullname: Charo – volume: 23 start-page: 7611 year: 2004 ident: 10.1593/neo.05823_bib32 article-title: Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells publication-title: Oncogene doi: 10.1038/sj.onc.1207970 contributor: fullname: Fulda – volume: 92 start-page: 1430 year: 2005 ident: 10.1593/neo.05823_bib64 article-title: HGSETRi, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602487 contributor: fullname: Pukac – volume: 9 start-page: 1031 year: 2002 ident: 10.1593/neo.05823_bib11 article-title: The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4401088 contributor: fullname: van Loo – volume: 7 start-page: 1166 year: 2000 ident: 10.1593/neo.05823_bib13 article-title: Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4400783 contributor: fullname: Korsmeyer – volume: 62 start-page: 1583 year: 2002 ident: 10.1593/neo.05823_bib33 article-title: Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindacmediated inhibition of Bcl-x(L) publication-title: Cancer Res contributor: fullname: Ravi – volume: 11 start-page: 5017s year: 2005 ident: 10.1593/neo.05823_bib46 article-title: Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-9006 contributor: fullname: Dunant – volume: 4 start-page: 1222 year: 2005 ident: 10.1593/neo.05823_bib44 article-title: Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinomacell lines publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-04-0186 contributor: fullname: Garcia-Morales – volume: J22 start-page: 3411 year: 2003 ident: 10.1593/neo.05823_bib51 article-title: The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 publication-title: EMBO doi: 10.1093/emboj/cdg315 contributor: fullname: Kramer – volume: 23 start-page: 6261 year: 2004 ident: 10.1593/neo.05823_bib59 article-title: Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/AP02-L in human malignant tumor cells publication-title: Oncogene doi: 10.1038/sj.onc.1207830 contributor: fullname: Nakata – volume: 104 start-page: 155 year: 1999 ident: 10.1593/neo.05823_bib19 article-title: Safety and antitumor activity of recombinant soluble Apo2 ligand publication-title: J Clin Invest doi: 10.1172/JCI6926 contributor: fullname: Ashkenazi – volume: 13 start-page: 21 year: 2004 ident: 10.1593/neo.05823_bib35 article-title: Histone deacetylase inhibitors in clinical development publication-title: Expert Opin Investig Drugs doi: 10.1517/13543784.13.1.21 contributor: fullname: Rosato – volume: 6 start-page: 1028 year: 1999 ident: 10.1593/neo.05823_bib7 article-title: Caspase structure, proteolytic substrates, and function during apoptotic cell death publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4400598 contributor: fullname: Nicholson – volume: 276 start-page: 36734 year: 2001 ident: 10.1593/neo.05823_bib50 article-title: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen publication-title: J Biol Chem doi: 10.1074/jbc.M101287200 contributor: fullname: Phiel – volume: 4 start-page: 186 year: 2002 ident: 10.1593/neo.05823_bib38 article-title: Phase I study of sequential deoxyazacytidine/depsipeptide infusion in patients with malignancies involving lungs or pleura publication-title: Clin Lung Cancer doi: 10.3816/CLC.2002.n.027 contributor: fullname: Schrump – volume: 350 start-page: 379 year: 2004 ident: 10.1593/neo.05823_bib63 article-title: Multidisciplinary management of lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMra035536 contributor: fullname: Spira – volume: 7 start-page: 139 year: 2004 ident: 10.1593/neo.05823_bib21 article-title: Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications publication-title: Drug Resist Updat doi: 10.1016/j.drup.2004.03.002 contributor: fullname: Shankar – volume: 314 start-page: 186 year: 2004 ident: 10.1593/neo.05823_bib66 article-title: Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2003.12.074 contributor: fullname: Neuzil – volume: 17 start-page: 1675 year: 1998 ident: 10.1593/neo.05823_bib15 article-title: Two CD95 (APO-1/Fas) signaling pathways publication-title: EMBO J doi: 10.1093/emboj/17.6.1675 contributor: fullname: Scaffidi – volume: 14 start-page: 337 year: 2003 ident: 10.1593/neo.05823_bib1 article-title: Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy publication-title: Cytokine Growth Factor Rev doi: 10.1016/S1359-6101(03)00029-7 contributor: fullname: Almasan – volume: 7 start-page: 383 year: 2001 ident: 10.1593/neo.05823_bib18 article-title: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions publication-title: Nat Med doi: 10.1038/86397 contributor: fullname: Lawrence – volume: 4 start-page: 549 year: 2005 ident: 10.1593/neo.05823_bib43 article-title: Histone deacetylase inhibitors in programmed cell death and cancer therapy publication-title: Cell Cycle doi: 10.4161/cc.4.4.1564 contributor: fullname: Marks – volume: 24 start-page: 4609 year: 2005 ident: 10.1593/neo.05823_bib61 article-title: HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma publication-title: Oncogene doi: 10.1038/sj.onc.1208585 contributor: fullname: Singh – volume: 99 start-page: 491 year: 2002 ident: 10.1593/neo.05823_bib29 article-title: Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis publication-title: Int J Cancer doi: 10.1002/ijc.10376 contributor: fullname: Evdokiou – volume: 9 start-page: 3578 year: 2003 ident: 10.1593/neo.05823_bib39 article-title: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously publication-title: Clin Cancer Res contributor: fullname: Kelly – volume: 144 start-page: 281 year: 1999 ident: 10.1593/neo.05823_bib72 article-title: Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner publication-title: J Cell Biol doi: 10.1083/jcb.144.2.281 contributor: fullname: Slee – volume: 3 start-page: 1397 year: 2004 ident: 10.1593/neo.05823_bib45 article-title: The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.1397.3.11 contributor: fullname: Doi – volume: 39 start-page: 633 year: 2000 ident: 10.1593/neo.05823_bib3 article-title: A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/ TRAIL publication-title: Biochemistry doi: 10.1021/bi992242l contributor: fullname: Hymowitz – volume: 11 start-page: 529 year: 2003 ident: 10.1593/neo.05823_bib9 article-title: A unified model for apical caspase activations publication-title: Mol Cell doi: 10.1016/S1097-2765(03)00051-0 contributor: fullname: Boatright – volume: 25 start-page: 111 year: 2001 ident: 10.1593/neo.05823_bib27 article-title: Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines publication-title: Am J Respir Cell Mol Biol doi: 10.1165/ajrcmb.25.1.4472 contributor: fullname: Liu – volume: 4 start-page: 551 year: 2002 ident: 10.1593/neo.05823_bib17 article-title: Defining characteristics of types I and II apoptotic cells in response to TRAIL publication-title: Neoplasia doi: 10.1038/sj.neo.7900270 contributor: fullname: Ozoren – volume: 62 start-page: 6108 year: 2002 ident: 10.1593/neo.05823_bib37 article-title: MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors publication-title: Cancer Res contributor: fullname: Jaboin – volume: 64 start-page: 1079 year: 2004 ident: 10.1593/neo.05823_bib49 article-title: Histone deacetylase is a target of valproic acid-mediated cellular differentiation publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-03-0799 contributor: fullname: Gurvich – volume: 45 start-page: 1207 year: 1994 ident: 10.1593/neo.05823_bib53 article-title: Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue publication-title: Mol Pharmacol contributor: fullname: Seynaeve – volume: 23 start-page: 2861 year: 2004 ident: 10.1593/neo.05823_bib16 article-title: Toxic proteins released from mitochondria in cell death publication-title: Oncogene doi: 10.1038/sj.onc.1207523 contributor: fullname: Saelens – volume: 32 start-page: 488 year: 2005 ident: 10.1593/neo.05823_bib36 article-title: Targeting the epigenome for the treatment and prevention of lung cancer publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2005.07.007 contributor: fullname: Schrump – volume: 12 start-page: 228 year: 2005 ident: 10.1593/neo.05823_bib22 article-title: Mechanisms of resistance to TRAIL-induced apoptosis in cancer publication-title: Cancer Gene Ther doi: 10.1038/sj.cgt.7700792 contributor: fullname: Zhang – volume: 95 start-page: 777 year: 2004 ident: 10.1593/neo.05823_bib2 article-title: TRAIL and its receptors as targets for cancer therapy publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2004.tb02181.x contributor: fullname: Yagita – volume: 349 start-page: 2241 year: 2003 ident: 10.1593/neo.05823_bib62 article-title: Esophageal cancer publication-title: N Engl J Med doi: 10.1056/NEJMra035010 contributor: fullname: Enzinger – volume: 9 start-page: 521 year: 2002 ident: 10.1593/neo.05823_bib69 article-title: Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis publication-title: Int J Mol Med contributor: fullname: Inoue – volume: 63 start-page: 621 year: 2003 ident: 10.1593/neo.05823_bib30 article-title: Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines publication-title: Cancer Res contributor: fullname: Kim – volume: 2 start-page: 1273 year: 2003 ident: 10.1593/neo.05823_bib67 article-title: Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells publication-title: Mol Cancer Ther contributor: fullname: Rosato – volume: 96 start-page: 10964 year: 1999 ident: 10.1593/neo.05823_bib8 article-title: Caspase activation: the inducedproximity model publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.96.20.10964 contributor: fullname: Salvesen – volume: 7 start-page: 646 year: 2005 ident: 10.1593/neo.05823_bib71 article-title: Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expres sions of cell cycle regulatory genes in multiple myeloma publication-title: Neoplasia doi: 10.1593/neo.04655 contributor: fullname: Fandy – volume: 7 start-page: 1101 year: 2000 ident: 10.1593/neo.05823_bib12 article-title: BID-dependent and BID-independent pathways for BAX insertion into mitochondria publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4400739 contributor: fullname: Ruffolo – volume: 98 start-page: 10833 year: 2001 ident: 10.1593/neo.05823_bib42 article-title: The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.191208598 contributor: fullname: Ruefli – volume: 304 start-page: 437 year: 2003 ident: 10.1593/neo.05823_bib14 article-title: Mechanisms of cytochrome c release by proapoptotic BCL-2 family members publication-title: Biochem Biophys Res Commun doi: 10.1016/S0006-291X(03)00615-6 contributor: fullname: Scorrano – volume: 64 start-page: 2580 year: 2004 ident: 10.1593/neo.05823_bib60 article-title: Cotreatment with histone deacetylase inhibitor LA0824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-03-2629 contributor: fullname: Guo – volume: 9 start-page: 3134 year: 2003 ident: 10.1593/neo.05823_bib25 article-title: Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis publication-title: Clin Cancer Res contributor: fullname: Kim – volume: 11 start-page: 255 year: 1999 ident: 10.1593/neo.05823_bib6 article-title: Apoptosis control by death and decoy receptors publication-title: Curr Opin Cell Biol doi: 10.1016/S0955-0674(99)80034-9 contributor: fullname: Ashkenazi – volume: 299 start-page: 31 year: 2001 ident: 10.1593/neo.05823_bib20 article-title: Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: charac terization of in vivo efficacy, pharmacokinetics, and safety publication-title: J Pharmacol Exp Ther contributor: fullname: Kelley – volume: 64 start-page: 4900 year: 2004 ident: 10.1593/neo.05823_bib26 article-title: Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with che motherapy to inhibit orthotopic lung tumor growth and improve survival publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-0408 contributor: fullname: Jin – volume: 10 start-page: 1141 year: 2004 ident: 10.1593/neo.05823_bib52 article-title: Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-03-0100 contributor: fullname: Takai – volume: 11 start-page: 542 year: 2005 ident: 10.1593/neo.05823_bib56 article-title: Depsipeptide (FR901228 enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts publication-title: Mol Ther doi: 10.1016/j.ymthe.2004.12.008 contributor: fullname: Vanoosten – volume: 20 start-page: 6969 year: 2001 ident: 10.1593/neo.05823_bib54 article-title: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells publication-title: EMBO J doi: 10.1093/emboj/20.24.6969 contributor: fullname: Gottlicher – volume: 271 start-page: 12687 year: 1996 ident: 10.1593/neo.05823_bib5 article-title: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family publication-title: J Biol Chem doi: 10.1074/jbc.271.22.12687 contributor: fullname: Pitti – volume: 11 start-page: S193 issue: 2 year: 2004 ident: 10.1593/neo.05823_bib65 article-title: Histone deacetylase inhibitors potentiate TNF-related apoptosisinducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4401535 contributor: fullname: Inoue – volume: 23 start-page: 5415 year: 2004 ident: 10.1593/neo.05823_bib28 article-title: Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP publication-title: Oncogene doi: 10.1038/sj.onc.1207704 contributor: fullname: Muhlethaler-Mottet – volume: 8 start-page: 274 year: 2002 ident: 10.1593/neo.05823_bib34 article-title: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax publication-title: Nat Med doi: 10.1038/nm0302-274 contributor: fullname: LeBlanc – volume: 94 start-page: 504 year: 2002 ident: 10.1593/neo.05823_bib41 article-title: Modulation of p53, ErbBI, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/94.7.504 contributor: fullname: Yu – volume: 25 start-page: 1813 year: 2004 ident: 10.1593/neo.05823_bib57 article-title: Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Spi sites in colon cancer cells publication-title: Carcinogenesis doi: 10.1093/carcin/bgh188 contributor: fullname: Kim – volume: 275 start-page: 24357 year: 2000 ident: 10.1593/neo.05823_bib70 article-title: Inhibition of death receptormediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD) publication-title: J Biol Chem doi: 10.1074/jbc.M000811200 contributor: fullname: Wajant – volume: 298 start-page: 560 year: 2004 ident: 10.1593/neo.05823_bib58 article-title: Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1) publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2004.04.038 contributor: fullname: Chopin – volume: 10 start-page: 2289 year: 2004 ident: 10.1593/neo.05823_bib40 article-title: A review of depsipeptide and other histone deacetylase inhibitors in clinical trials publication-title: Curr Pharm Des doi: 10.2174/1381612043383980 contributor: fullname: Piekarz – volume: 118 start-page: 230 year: 2005 ident: 10.1593/neo.05823_bib23 article-title: Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis inducing ligand against esophageal squamous cell carcinoma publication-title: Int J Cancer doi: 10.1002/ijc.21283 contributor: fullname: Kondo – volume: 334 start-page: 168 year: 1996 ident: 10.1593/neo.05823_bib48 article-title: Antiepileptic drugs publication-title: N Engl J Med doi: 10.1056/NEJM199601183340308 contributor: fullname: Brodie – volume: 66 start-page: 1537 year: 2003 ident: 10.1593/neo.05823_bib68 article-title: The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis publication-title: Biochem Pharmacol doi: 10.1016/S0006-2952(03)00509-4 contributor: fullname: Zhang – volume: 60 start-page: 619 year: 1998 ident: 10.1593/neo.05823_bib10 article-title: The mitochondrial death/life regulator in apoptosis and necrosis publication-title: Annu Rev Physiol doi: 10.1146/annurev.physiol.60.1.619 contributor: fullname: Kroemer |
SSID | ssj0016177 |
Score | 2.0863373 |
Snippet | Inhibitors of histone deacetylases have been shown to enhance the sensitivity of cancer cells to tumor necrosis factor-related apoptosis-inducing ligand... |
SourceID | doaj crossref pubmed elsevier |
SourceType | Open Website Aggregation Database Index Database Publisher |
StartPage | 446 |
SubjectTerms | Apo2L/TRAIL Apoptosis Apoptosis Regulatory Proteins - metabolism BcI2 Carcinoma, Non-Small-Cell Lung - drug therapy caspases Caspases - metabolism Cell Line, Tumor Dose-Response Relationship, Drug Drug Evaluation, Preclinical Enzyme Activation Enzyme Inhibitors - pharmacology Epilepsy - drug therapy esophageal cancer Histone deacetylase inhibitor Histone Deacetylase Inhibitors Humans lung cancer Lung Neoplasms - drug therapy malignant pleural mesothelioma Membrane Glycoproteins - metabolism mitochondria Mitochondria - enzymology Thoracic Neoplasms - drug therapy TNF-Related Apoptosis-Inducing Ligand Tumor Necrosis Factor-alpha - metabolism Valproic Acid - pharmacology |
SummonAdditionalLinks | – databaseName: Elsevier Free Content dbid: IXB link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBYhh9JL6bvbF0PpcV0_JDnW0fE2JCVbSrspezN6OTEs9rI40PzR_p7OyN60gVx68UGMZaH5PPNJI80w9tHrphDodiPFRR4Jy1VUmCN88EzqgiAULoUtv-anF-LLWq4PWLW_C0PHKifbP9r0YK2nlniazXjbtvGPVBzlUhY5VY-g-BnaYcrtSZf41se3kQT00KHACgpHJD1lF5KKx53vPyWyyPgdnxRS99_nmv7xOyeP2aOJMEI5jukJO_DdU_ZgOYXEn7HfP_UGrWBrobStm4PuoOyG1m_xd0dzYGGxu74E2m6FkBKk87BAM-iHG-TNHs66q9a0FGnH98dKEnP41g90iIhoKCBBhOpm6If-F3Y2JjuGvoFy22fn8ep7eXYOfQdjak7vYHWFoLIoWhGedlD5zYZ6CeWAYImfQoPbOcR9tJgK8A4oi4YNRxOGELDynF2cfF5Vp9FUrCGyuIIZkKXrzEsrmwYpJpI2b51oXGa1Ej7RWarTwpqk0VpZy3OkaU2qE5JPtZTWcf6CHXY4B68YOKdwZVg4xEwq6IwZN4I3zprCuqRQyYx92Kur3o45OWpay6BOa9RpHXQ6Y8ekyFsBSqMdGvrdZT3hqLYuE8akSholRZMpbZRHb51ynRjHtZmx-R4G9R1UYlftfd98OULl77DygsJPyev_6-gNezhu9dBuz1t2OOyu_TskP4N5H9D9B6QxBpU priority: 102 providerName: Elsevier |
Title | Valproic Acid, an Antiepileptic Drug with Histone Deacetylase Inhibitory Activity, Potentiates the Cytotoxic Effect of Apo2L/TRAIL on Cultured Thoracic Cancer Cells through Mitochondria-Dependent Caspase Activation |
URI | https://dx.doi.org/10.1593/neo.05823 https://www.ncbi.nlm.nih.gov/pubmed/16820090 https://doaj.org/article/cd24bb195b954f29ab9e47113a0bd3ab |
Volume | 8 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlhdJL6bvbRxhKj-uubUmOdHS8DdmSTUvZlKUXo5cbw2IviwPNH-3v6UjytikEeulFByNLg-bzzCeNPEPIO6cawdDtJpKyImGGykToI2xozpXwEAo_hS3Pi9ML9nHN1zdKffk7YTE9cFy4mbE50zqTXEvOmlwqLR0a1IyqVFuqdLC-Gd9vpsb4AfrlUFaFHRUJ56IYcwpxSWed69-nXOT0L08UEvbf5pBueJuTh-TBSBOhjOI9Indc95jcW46B8Cfk51e1QdvXGihNa6egOii7oXVb_MjRCBiY766-gz9khZAIpHMwR-Pnhmtkyw4W3WWrWx9fx_dj_YgpfO4Hf3XIk09AWgjV9dAP_Q8cLKY4hr6BctvnZ7PVl3JxBn0HMSGns7C6RCgZ7Fp5FO2gcpuNHyUUAYIlToVmtrOI9mQ-lt0dsC-aM5QmiBAQ8pRcnHxYVafJWKIhMbhvGZCbq9xxw5sGiSVSNWcsa2xulGQuVXmmMmF02igljaEFkrMmU6nvnynOjaX0GTnocA1eELBW4n5QWERKxvzNMqoZbazRwthUyHRC3u7VVW9jJo7a72BQpzXqtA46nZBjr8jfHXzy7PAAIVWPkKr_BakJme5hUI88JPILHKq9bc7nESp_xCqEDzqlL_-HNK_I_Xjs409-XpODYXfl3iARGvRhwDy2i_XxIbl7Xq0_ffsF4SAMQw |
link.rule.ids | 315,786,790,870,2115,3525,27955,27956,45907 |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwELaWRQIuiDflOUIcG5rEdtY-ZlNWLbQrBF3UW-RXdiNVSVVlJfaP8nsYO-nCSnvhkoM1cSzPl5nPHnuGkI9OVYKh240kZVnEDJWR0Ef4oClXwkMoXApbnmazM_ZlzdcHpNjfhfHHKgfb39v0YK2Hlskwm5NtXU9-JOwo41xkvnqEj5_dIXcZx7Wev8W3Pr4OJaCLDhVWUDry4kN6IS7ppHHtp5iLlN5wSiF3_22-6R_Hc_KIPBwYI-T9oB6TA9c8IfeWQ0z8Kfn9U23QDNYGclPbMagG8qar3Rb_d7QHBqa7y3Pw-60QcoI0DqZoB113hcTZwby5qHXtQ-34fl9KYgzf2s6fIvI8FJAhQnHVtV37Czvrsx1DW0G-bdPFZPU9ny-gbaDPzeksrC4QVQZFCw-oHRRus_G9hHpAsMRPocVtLAI_mg4VeDuURcuGowlDCGB5Rs5OPq-KWTRUa4gMLmE6pOkqddzwqkKOiazNGcsqmxolmYtVmqhEGB1XSkljaIY8rUpU7OUTxbmxlD4nhw3OwUsC1kpcGgqLoEmYP2RGNaOVNVoYGwsZj8iHvbrKbZ-Uo_SLGdRpiTotg05H5Ngr8lrA59EODe3uvByAVBqbMq0TybXkrEql0tKhu06oirWlSo_IeA-D8gYssav6tm--6KHyd1iZ8PGn-NX_dfSe3J-tlotyMT_9-po86Pd9_NbPG3LY7S7dW2RCnX4XkP4H5G4Jug |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Valproic+Acid%2C+an+Antiepileptic+Drug+with+Histone+Deacetylase+Inhibitory+Activity%2C+Potentiates+the+Cytotoxic+Effect+of+Apo2L%2FTRAIL+on+Cultured+Thoracic+Cancer+Cells+through+Mitochondria-Dependent+Caspase+Activation&rft.jtitle=Neoplasia+%28New+York%2C+N.Y.%29&rft.au=M.+Firdos+Ziauddin&rft.au=Wen-Shuz+Yeow&rft.au=Justin+B.+Maxhimer&rft.au=Aris+Baras&rft.date=2006-06-01&rft.pub=Elsevier&rft.issn=1476-5586&rft.eissn=1522-8002&rft.volume=8&rft.issue=6&rft.spage=446&rft.epage=457&rft_id=info:doi/10.1593%2Fneo.05823&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_cd24bb195b954f29ab9e47113a0bd3ab |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-5586&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-5586&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-5586&client=summon |